[ { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#Head", "@graph": [ { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk", "http://www.nanopub.org/nschema#hasAssertion": [ { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance": [ { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo": [ { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#pubinfo" } ], "@type": [ "http://www.nanopub.org/nschema#Nanopublication" ] } ] }, { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#assertion", "@graph": [ { "@id": "http://purl.obolibrary.org/obo/DOID_1558", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#association", "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [ { "@id": "http://purl.obolibrary.org/obo/DOID_1558" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [ { "@id": "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [ { "@id": "https://identifiers.org/drugbank:DB00722" } ], "@type": [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "\"PRINIVIL is contraindicated in patients with: a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor hereditary or idiopathic angioedema. Do not coadminister aliskiren with PRINIVIL in patients with diabetes [see Drug Interactions (7.4) PRINIVIL is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer PRINIVIL within 36 hours of switching to or from sacubitril/valsartan, a product containing a neprilysin inhibitor [see Warnings and Precautions (5.2) Drug Interactions (7.8) Angioedema or a history of hereditary or idiopathic angioedema ( 4 Hypersensitivity ( 4 Coadministration of aliskiren with PRINIVIL in patients with diabetes ( 4 7.4 PRINIVIL is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer PRINIVIL within 36 hours of switching to or from sacubitril/valsartan, a product containing a neprilysin inhibitor ( 4\"" } ], "https://w3id.org/biolink/vocab/provided_by": [ { "@id": "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation": [ { "@id": "https://schema.org/MedicalContraindication" } ] }, { "@id": "https://identifiers.org/drugbank:DB00722", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Drug" } ] } ] }, { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#pubinfo", "@graph": [ { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#sig", "http://purl.org/nanopub/x/hasAlgorithm": [ { "@value": "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey": [ { "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature": [ { "@value": "TGKotDMizhLpKLj1hlHyxQ8SVIw8wUoeTur0vtFLNSzbYvfk4aAZd6ydLbBDdO1sHcomTJFZP6sOt6AwZa6ticlDtFyVOHm5dI5T3J7cRKAhseshr9SbfsAnuRwAqwrbYfY0Y89YIOaqD029hYsjlJ1XTguhBzKR4vZF002DojQ=" } ], "http://purl.org/nanopub/x/hasSignatureTarget": [ { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk" } ] }, { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk", "http://purl.org/dc/terms/created": [ { "@value": "2021-08-23T12:15:44.690+02:00", "@type": "http://www.w3.org/2001/XMLSchema#dateTime" } ], "http://purl.org/dc/terms/creator": [ { "@id": "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [ { "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [ { "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [ { "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] } ] }, { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#provenance", "@graph": [ { "@id": "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#assertion", "http://www.w3.org/ns/prov#wasAttributedTo": [ { "@id": "https://orcid.org/0000-0002-1468-3557" } ] } ] } ]